^
Association details:
| Biomarker: | TYMS underexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy.
Published date:
01/11/2021
Excerpt:
Eighty-one (77.1%) of 105 patients provided material for this analysis. A lower pre-treatment expression of TYMS was associated with clinical benefit (PR and SD; p = 0.021).
Secondary therapy:
5-fluorouracil + oxaliplatin + arfolitixorin
Trial ID:
